Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.33 |
| ▸ | STAT6 | P42226 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749038 | 0.89 | ADORA3 (0.39) | SYKL3MBTL1NTRK1JAK3JAK2 | |
| SCHEMBL30748952 | 0.87 | SYK (0.37) | SYKL3MBTL1JAK3JAK2JAK1 | |
| SCHEMBL30748933 | 0.87 | SYK (0.40) | SYKL3MBTL1JAK3JAK2JAK1 | |
| SCHEMBL30749137 | 0.87 | TRPV1 (0.35) | SYK | |
| SCHEMBL30748787 | 0.87 | L3MBTL1 (0.36) | SYKL3MBTL1JAK3JAK2JAK1 | |
| SCHEMBL30749048 | 0.86 | NTRK1 (0.31) | SYKL3MBTL1NTRK1ALDH1A1 | |
| SCHEMBL30748754 | 0.81 | XDH (0.36) | L3MBTL1ALDH1A1 | |
| SCHEMBL30749139 | 0.76 | MAOB (0.41) | SYKJAK3ALDH1A1 | |
| SCHEMBL30749110 | 0.74 | MAPT (0.33) | SYKL3MBTL1ALDH1A1 | |
| SCHEMBL31691413 | 0.74 | TRPV1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | SYK 2316/4885L3MBTL1 517/4885NTRK1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.